Reference intervals (RIs) for vitamin B6 biomarkers remain underexplored in Chinese adults. We aimed to establish age- and sex-specific RIs of pyridoxal 5′-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (PA), and their ratios (PLP/PL, PLP/PA, and PAr), and to identify independent determinants of these markers.
Methods
Vitamin B6 metabolites were measured by liquid chromatography–tandem mass spectrometry (LC–MS/MS). The distribution changes were illustrated by sex-stratified age percentile curves (P10/P50/P90). Robust 95% RIs (P2.5–P97.5) were obtained by sex and age (<50 vs. ≥50 years) using the Horn–Pesce method. Sex-stratified multivariable linear regression was conducted to identify the independent determinants of vitamin B6 biomarkers.
Results
This study included a community-based sample of 367 healthy adults (197 males and 170 females) with a median age of 49.0 years (range 20.0–80.0 years). Females had higher PLP, PL and PLP/PA, and lower PAr than males (all p < 0.01). In males, percentile curves and age-group contrasts showed age-associated declines in PLP, PLP/PL and PLP/PA and an increase in PAr (all p < 0.05); corresponding indices in females were largely stable. The RIs of PLP (nmol/L) were 10.36–145.87 (males <50 years, n = 103), 13.03–103.46 (females <50 years, n = 87), 9.27–142.96 (males ≥50 years, n = 94), and 16.83–173.06 (females ≥50 years, n = 83), respectively. Higher ALP levels were associated with lower PLP, PLP/PL and PLP/PA, and higher PAr; albumin was positively related to PLP/PL and PLP/PA, and negatively to PAr; eGFR was positively correlated with PLP/PA, and negatively with PAr. Notably, serum phosphorus was positively associated with PLP, PLP/PL and PLP/PA, and negatively with PAr.
Conclusion
We established population-specific, age- and sex-stratified RIs for vitamin B6 biomarkers in healthy Chinese adults, providing a baseline for clinical and laboratory assessment of vitamin B6 metabolism. We also found that ALP, albumin, renal function, and serum phosphorus were closely related to the vitamin B6 status in both males and females.
4-pyridoxic acidmultivariate linear regressionpyridoxalpyridoxal 5′-phosphatereference intervalThe author(s) declared that financial support was received for this work and/or its publication. This study was funded by the National Natural Science Foundation of China (U23A20411, 82470920).section-at-acceptanceNutritional EpidemiologyIntroduction
Vitamin B6 status is routinely assessed using circulating pyridoxal 5′-phosphate (PLP), yet accumulating evidence suggests that single vitamers provide an incomplete picture of vitamin B6 metabolism (1–3). PLP, pyridoxal (PL), and 4-pyridoxic acid (PA) reflect distinct functional and catabolic states, and composite indices such as PLP/PL, PLP/PA, and PAr = PA/(PLP + PL) have been proposed to capture the balance between coenzyme supply and degradation (2). These ratio-based markers are considered more stable indicators of vitamin B6 functional status, being less influenced by transient dietary intake and several confounding conditions (2, 4, 5). The recent cohort studies further showed that composite indices reflecting the PLP and PA balance, including PA/PLP and PAr, predict morbidity and mortality more strongly than PLP alone (6–9), supporting the incorporation of these composite markers into the evaluation of vitamin B6 status.
However, interpretation of vitamin B6 biomarkers is complicated by their sensitivity to ethnicity, diet and supplement use, inflammation, renal dysfunction, altered alkaline phosphatase (ALP) activity, hypoalbuminemia, and other metabolic perturbations (2, 9–12). These factors can change PLP, PL, PA and related ratios independently of vitamin B6 intake, underscoring the need for robust, population-specific reference intervals (RIs) to guide clinical and epidemiologic use. Existing data are dominated by Western cohorts and focus primarily on PLP, with limited concurrent measurement of PL, PA and ratio-based indices, and scarce exploration of age- and sex-specific patterns in Asian populations (4, 10, 13, 14). Whether healthy Chinese adults exhibit distinct distributions of PLP, PL, PA and related ratios, and how these markers vary by age, sex, and key biochemical determinants, remain largely unknown. Importantly, individuals with reduced ALP activity, such as those with hypophosphatasia (HPP), caused by loss of function mutations of ALPL gene, are characterized by significantly elevated circulating PLP levels (15–17). Establishing RIs of vitamin B6, especially for PLP, may therefore facilitate earlier identification of HPP.
Therefore, we conducted a community-based study of rigorously screened healthy Chinese adults with two objectives: (1) to establish age- and sex-specific RIs for PLP, PL, PA and their ratios (PLP/PL, PLP/PA, PAr) using the methods recommended by the CLSI EP28-A3c guidelines; and (2) to identify independent biochemical determinants of vitamin B6 biomarkers.
Materials and methodsStudy design and participants
This study was approved by the Ethics Committee of Shanghai Sixth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine (Approved no. 2024-KY-135(K)). Written informed consent was obtained from all participants prior to enrollment.
A community-based sample of adults (aged ≥18 years) in Shanghai was recruited from July to October 2024 to establish age- and sex-specific RIs for plasma vitamin B6 metabolites. Detailed demographic, anthropometric, and clinical data were collected, including age, sex, height, weight, body mass index (BMI), and blood pressure. Each participant underwent a standardized health examination and completed a validated questionnaire addressing lifestyle behaviors, smoking and drinking habits, and current medication use. Participants were excluded if they were pregnant or lactating, had BMI ≥ 30 kg/m2 or <18.5 kg/m2, were current smokers, or had alcohol use disorder, anemia, hypertension, diabetes mellitus, dyslipidemia, hypoalbuminemia (<35 g/L), chronic kidney (eGFR <60 mL/min/1.73 m2) or liver disease, abnormal ALP levels (<40 U/L or >125 U/L), systemic inflammation (CRP ≥ 5 mg/L), active malignancy, thyroid dysfunction, or recent vitamin B6 supplementation within 1 week.
Biochemical measurements
Fasting venous blood samples were collected between 8:00 and 10:00 a.m. following an overnight fast and protected from light until analysis. All measurements were performed in a single batch using the same reagent lot and following standardized laboratory quality control protocols. Complete blood count (CBC) and C-reactive protein (CRP) were analyzed using an AU5811 hematology analyzer (Beckman Coulter, Brea, CA, USA). Serum levels of calcium, phosphorus, alanine aminotransferase (ALT), ALP, creatinine, uric acid, total cholesterol (TC), triglycerides (TG), and glycated hemoglobin (HbA1c) were measured with a Hitachi 7,600 automatic biochemical analyzer (Hitachi Ltd., Tokyo, Japan). The estimated GFR (eGFR) was calculated using the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (18). Reference ranges were obtained from the Department of Laboratory Medicine, Shanghai Sixth People’s Hospital.
Plasma levels of PLP, PL and PA were quantified using liquid chromatography–tandem mass spectrometry (LC–MS/MS) with the Diasis Water-Soluble Vitamin Sample Extraction Kit (Zhejiang Diasis Diagnostic Technologies Co., Ltd., China), following the manufacturer’s protocol. For PLP, intra-assay coefficients of variation (CVs) were 6.22% (LQC) and 4.73% (HQC), and inter-assay CVs were 7.85% (LQC) and 5.23% (MQC). For PL, intra-assay CVs were 1.07% (LQC) and 1.34% (HQC), and inter-assay CVs were 2.62% (LQC) and 2.52% (MQC). For PA, intra-assay CVs were 3.77% (LQC) and 4.11% (HQC), and inter-assay CVs were6.39% (LQC) and 3.13% (MQC).
Statistical analysis
Continuous variables were tested for normality using the Shapiro–Wilk test. Variables with an approximately normal distribution were presented as mean ± standard deviation and were compared using independent-samples t tests or one-way ANOVA, with Levene’s test applied to assess homogeneity of variance. Non-normally distributed variables were reported as median (Q1, Q3) and were compared using the Mann–Whitney U test or Kruskal–Wallis’s test, as appropriate.
Prior to RI establishment, we evaluated potential outliers within each subgroup (sex and age group) using Tukey’s interquartile-range (IQR) fences (1.5 × IQR for mild and 3 × IQR for extreme values). Then, based on the analysis of quality control records, raw data, consistency with exclusion criteria, and possible supplement use or recent medical history, each value marked as an outlier was individually reviewed. Due to the absence of evidence of measurement errors, sample handling issue, or violations of exclusion criteria, all values were retained. RIs were established using CLSI EP28-A3c-recommended robust methods to mitigate the impact of extreme values.
Sex-specific age–percentile curves (P10/P50/P90) were generated to visualize distributional shifts across adulthood. RIs for vitamin B6 metabolites were established after stratification by age (<50 vs. ≥50 years) and sex. The cutoff age of 50 was mainly based on the following four points: Firstly, it was close to the median age of our cohort (49 years old). Secondly, a previous study establishing age- and sex-specific RIs of PLP levels also used 50 years as the cutoff. Thirdly, we found that the age of 50 was the point where significant changes occurred in the sex-specific percentile curves. Fourthly, the age of 50 is widely recognized as the midlife boundary, which is associated with physiological changes such as menopausal hormone changes (19). The robust method described by Horn and Pesce (20) was applied to estimate 95% RIs (P2.5–P97.5) due to the sample sizes of subgroups below 120, in accordance with the CLSI EP28-A3c guideline. The stability of the estimated intervals was further verified using nonparametric bootstrap resampling.
To explore factors associated with vitamin B6 metabolites, multivariate linear regression by sex was performed. Outcome variables (e.g., PLP, PLP/PL) were naturally log-transformed to meet model assumptions. Covariates included age, BMI, ALP, ALT, eGFR, CRP, calcium, phosphorus, and albumin.
All statistical analyses were conducted using R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria), with a two-tailed p value < 0.05 considered statistically significant.
ResultsCharacteristics of the study population
This study included 367 healthy individuals (197 males and 170 females) with a median age of 49.0 years (range 20.0–80.0 years) (Figure 1). Baseline characteristics by sex were shown in Table 1. The age between males and females did not differ (49.0 (Q1, Q3: 32.0, 60.0) years vs. 48.0 (Q1, Q3: 35.0, 61.0) years; p = 0.617). Significant sex-related differences were observed in height, weight, BMI, SBP, DBP, cholesterol, albumin, ALP, HGB, ALT, eGFR, uric acid, and phosphorus levels (all p < 0.05). Females exhibited significantly higher levels of PLP, PL and PLP/PA, and lower PAr compared to males (all p < 0.01), whereas PA and PLP/PL levels were comparable between sex.
Study flowchart. BMI, body mass index; ALP, alkaline phosphatase; CRP, C-reactive protein; PLP, pyridoxal 5′-phosphate; PL, pyridoxal; PA, 4-pyridoxic acid; LC–MS/MS, liquid chromatography–tandem mass spectrometry.
Flowchart illustrating recruitment and exclusion process for a study on plasma vitamin B6 metabolites in Shanghai adults, detailing initial sample of 900, multiple exclusion criteria, and final stratification of 367 eligible subjects by age and sex.
Baseline characteristics by sex in the healthy population.
Variable
Total (n = 367)
Male (n = 197)
Female (n = 170)
p value
Age (years)
49.0 (33.0, 60.0)
49.0 (32.0, 60.0)
48.0 (35.0, 61.0)
0.617
Height (cm)
167.2 (162.0, 174.8)
174.0 (170.0, 178.3)
161.8 (157.5, 165.2)
<0.001
Weight (kg)
63.3 (55.6, 72.0)
70.3 (64.2, 76.2)
56.0 (51.2, 60.8)
<0.001
BMI (kg/m2)
22.5 (20.6, 24.5)
23.5 (21.7, 25.4)
21.6 (19.7, 23.5)
<0.001
SBP (mmHg)
123.0 (111.0, 136.0)
126.0 (116.0, 136.0)
117.0 (106.0, 134.0)
0.001
DBP (mmHg)
75.0 (69.0, 83.0)
78.0 (72.0, 85.0)
72.0 (65.0, 78.0)
<0.001
Cholesterol (mmol/L)
4.9 (4.4, 5.5)
4.8 (4.2, 5.3)
5.0 (4.6, 5.7)
<0.001
Triglyceride (mmol/L)
1.1 (0.8, 1.6)
1.1 (0.8, 1.6)
1.0 (0.8, 1.6)
0.034
CRP (mg/L)
0.5 (0.2, 0.9)
0.5 (0.2, 1.0)
0.5 (0.2, 0.9)
0.745
HGB (g/L)
144.5 ± 14.8
154.4 ± 10.6
132.8 ± 9.5
<0.001
Albumin (g/L)
45.9 ± 2.4
46.3 ± 2.5
45.3 ± 2.3
<0.001
ALT (U/L)
18.0 (13.0, 25.0)
20.0 (15.0, 28.0)
15.5 (12.0, 21.2)
<0.001
HbA1c (%)
5.50 (5.20, 5.80)
5.50 (5.20, 5.80)
5.40 (5.20, 5.70)
0.542
eGFR (mL/min/1.732)
94.7 (85.0, 104.4)
92.9 (85.0, 101.0)
97.6 (85.8, 107.0)
<0.001
Uric acid (μmol/L)
341.0 (285.5, 396.5)
387.0 (336.5, 426.0)
291.5 (252.8, 338.2)
<0.001
Calcium (mmol/L)
2.37 (2.30, 2.43)
2.4 (2.3, 2.4)
2.37 (2.32, 2.43)
0.489
Phosphorus (mmol/L)
1.08 ± 0.14
1.03 ± 0.14
1.14 ± 0.11
<0.001
ALP (U/L)
69.0 (59.0, 82.0)
71.0 (63.0, 82.0)
66.0 (55.8, 82.0)
0.006
PLP (nmol/L)
35.48 (26.07, 49.24)
32.47 (24.86, 46.11)
39.24 (28.65, 50.36)
0.004
PL (nmol/L)
14.91 (11.63, 18.05)
14.12 (11.15, 16.73)
15.67 (12.49, 18.96)
0.003
PA (nmol/L)
15.79 (12.81, 20.26)
16.18 (13.16, 19.80)
15.29 (12.50, 20.81)
0.959
PLP/PL
3.57 (2.98, 4.24)
3.50 (2.91, 4.27)
3.72 (3.11, 4.20)
0.216
PLP/PA
2.94 (2.25, 4.12)
2.69 (2.17, 3.87)
3.20 (2.36, 4.35)
0.003
PAr
0.26 (0.20, 0.33)
0.28 (0.21, 0.36)
0.25 (0.18, 0.32)
0.003
Normally distributed variables were compared using independent t-tests and reported as mean ± standard deviation, while non-normally distributed variables were analyzed with Mann–Whitney U tests and summarized as median (Q1, Q3). Categorical variables were presented as frequency (percentage) and analyzed using Pearson’s chi-square. Statistical significance was defined as two-tailed p < 0.05, with significant results bold. PAr = PA/(PLP + PL). Normal reference ranges for indices: Cholesterol: 2.80–5.90 mmol/L; Triglyceride: 0.45–1.81 mmol/L; CRP: 0–5 mg/L; HGB: 115–150 g/L; Albumin:35.0–55.0 g/L; ALT: 0–65 U/L; HbA1c: 4.3–6.5%; eGFR ≥ 60 mL/min/1.732; Uric acid: 210–430 μmol/L; serum calcium: 2.08–2.60 mmol/L; serum phosphorus: 0.80–1.60 mmol/L; ALP: 45–125 U/L (Male), 35–100 U/L (Female). BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CRP, C-reactive protein; HGB, hemoglobin; ALT, alanine aminotransferase; HbA1c, glycated hemoglobin; ALP, alkaline phosphatase; PLP, pyridoxal 5′-phosphate; PL, pyridoxal; PA, 4-pyridoxic acid.
Age- and sex-related variations and RIs of vitamin B6 metabolites
The sex-stratified age-percentile curves (P10/P50/P90) revealed distinct age-related patterns of plasma PLP, PL and PA levels, as well as their ratios (PLP/PL, PLP/PA, PAr) (Supplementary Figure 1). After grouping by age (<50 years and ≥50 years), inter group comparisons were conducted for males and females, respectively (Table 2). In males, PLP in ≥50-year-old group was significantly lower than that in the <50-year-old group (p = 0.039). PA showed a slight and insignificant age-related trend, while PL remained relatively stable across different age groups. Consistent with the curve, the decrease in PLP/PL and PLP/PA, as well as the increase in PAr, were more significant in those aged ≥50 years (all p < 0.01). In females, PL and PA increased slightly with age and the levels in ≥50-year-old group were significantly higher than those in <50-year-old group (both p < 0.01). However, there were no significant differences in PLP, PLP/PL, PLP/PA, and PAr between the two age groups (all p > 0.05). These distribution changes suggest that RIs need to be stratified by age and sex.
Sex-stratified comparisons of vitamin B6 biomarkers between participants aged <50 and ≥50 years.
Variable
Males
Females
<50 years
≥50 years
p value
<50 years
≥50 years
p value
PLP (nmol/L)
38.44 (26.22, 50.54)
31.68 (23.91, 40.54)
0.039
39.65 (27.43, 56.85)
41.38 (31.08, 50.17)
0.185
PL (nmol/L)
14.66 (11.25, 17.65)
14.00 (11.01, 16.27)
0.457
14.78 (11.61, 17.95)
16.99 (14.24, 19.92)
0.002
PA (nmol/L)
15.67 (12.94, 18.07)
17.25 (13.76, 21.35)
0.080
15.23 (11.68, 18.84)
18.45 (14.14, 22.87)
0.001
PLP/PL
3.82 ± 1.13
3.39 ± 0.83
0.002
3.79 ± 0.85
3.58 ± 0.83
0.097
PLP/PA
3.27 (2.27, 4.21)
2.64 (1.87, 3.36)
0.001
3.50 (2.35, 4.49)
3.25 (2.32, 4.23)
0.271
PAr
0.25 (0.19, 0.33)
0.31 (0.24, 0.39)
0.002
0.25 (0.18, 0.32)
0.26 (0.19, 0.32)
0.373
Statistical significance was defined as two-tailed p < 0.05, with significant results bold. PAr = PA/(PLP + PL). PLP, pyridoxal 5′-phosphate; PL, pyridoxal; PA, 4-pyridoxic acid.
The 95% RIs (P2.5–P97.5) for six vitamin B6–related biomarkers (PLP, PL, PA, PLP/PL, PLP/PA, and PAr), stratified by sex and age group (<50 years and ≥50 years), were summarized in Table 3. Sample sizes were 103 for males <50 years, 87 for females <50 years, 94 for males ≥50 years, and 83 for females ≥50 years, respectively.
Reference intervals of vitamin B6 metabolites stratified by age and sex.
Variable
Age group
Sex
n
Median (Q1, Q3)
P2.5 (95%CI)
P97.5 (95%CI)
PLP (nmol/L)
<50 years
Male
103
38.44 (26.22, 50.54)
10.36 (7.49–16.91)
145.87 (84.12–150.60)
Female
87
39.65 (27.43, 56.85)
13.03 (7.08–17.03)
103.46 (71.05–115.04)
≥50 years
Male
94
31.68 (23.91, 40.54)
9.27 (8.21–14.16)
142.96 (79.11–166.95)
Female
83
41.38 (31.08, 50.17)
16.83 (15.58–20.11)
173.06 (122.80–189.85)
PL (nmol/L)
<50 years
Male
103
14.66 (11.25, 17.65)
7.18 (6.10–8.61)
49.95 (26.74–66.34)
Female
87
14.78 (11.61, 17.95)
7.48 (7.12–9.33)
37.87 (24.65–52.11)
≥50 years
Male
94
14.00 (11.01, 16.27)
6.58 (5.08–8.14)
54.62 (30.87–65.87)
Female
83
16.99 (14.24, 19.92)
7.78 (6.34–9.99)
71.43 (37.75–72.74)
PA (nmol/L)
<50 years
Male
103
15.67 (12.94, 18.07)
8.19 (6.39–10.21)
47.66 (32.32–67.21)
Female
87
15.23 (11.68, 18.84)
8.03 (5.84–8.68)
35.60 (27.52–44.61)
≥50 years
Male
94
17.25 (13.76, 21.35)
9.23 (7.53–10.26)
46.35 (31.34–66.11)
Female
83
18.45 (14.14, 22.87)
9.34 (7.32–11.25)
52.90 (34.72–54.43)
PLP/PL
<50 years
Male
103
3.79 (2.94, 4.69)
1.72 (1.38, 2.19)
6.25 (5.78, 6.89)
Female
87
3.77 (3.22, 4.25)
2.18 (1.43, 2.62)
6.00 (5.05, 6.19)
≥50 years
Male
94
3.37 (2.82, 3.96)
1.87 (1.73, 2.05)
4.95 (4.71, 6.04)
Female
83
3.57 (2.89, 4.11)
2.05 (2.00, 2.36)
5.26 (4.99, 5.32)
PLP/PA
<50 years
Male
103
3.27 (2.27, 4.21)
1.03 (0.80–1.52)
6.95 (5.81–7.36)
Female
87
3.50 (2.35, 4.49)
1.71 (1.18–1.90)
7.74 (6.05–10.28)
≥50 years
Male
94
2.64 (1.87, 3.36)
0.76 (0.57–1.34)
5.38 (4.63–8.25)
Female
83
3.25 (2.32, 4.23)
1.46 (1.28–1.85)
6.42 (5.11–7.73)
PAr
<50 years
Male
103
0.26 (0.19, 0.33)
0.12 (0.12–0.14)
0.61 (0.48–0.76)
Female
87
0.25 (0.18, 0.32)
0.11 (0.08–0.14)
0.44 (0.40–0.50)
≥50 years
Male
94
0.31 (0.24, 0.39)
0.15 (0.10–0.17)
0.89 (0.56–1.17)
Female
83
0.26 (0.19, 0.32)
0.13 (0.10–0.16)
0.48 (0.39–0.53)
The robust method based on Horn’s algorithm was used to calculate 95% reference intervals (P2.5–P97.5), and their stability was validated via nonparametric bootstrap resampling. PLP, pyridoxal 5′-phosphate; PL, pyridoxal; PA, 4-pyridoxic acid.
Factors associated with vitamin B6 metabolites
Sex-stratified multivariate linear regression was conducted to identify independent determinants of vitamin B6 metabolites (Figure 2; Supplementary Tables 1 and 2), and effect directions were broadly similar in males and females. The serum ALP level was negatively correlated with plasma PLP levels and PLP based ratios (PLP/PL, PLP/PA), whereas positively correlated with PAr. The serum albumin level was positively correlated with PLP/PL and PLP/PA, and negatively correlated with PAr. Higher eGFR was associated with lower PAr and higher PLP/PA, while serum phosphorus levels were positively correlated with PLP and their ratios (PLP/PL, PLP/PA), and negatively correlated with PAr. However, age, BMI, ALT, CRP, and calcium showed non-significant associations with vitamin B6 metabolites after multivariable adjustment.
Sex-stratified multivariable linear regression forest plot of vitamin B6 biomarkers. The regression coefficients (standardized β values) and 95% confidence intervals (CIs) are presented for each variable. (A) PLP, (B) PL, (C) PA, (D) PLP/PL, (E) PLP/PA, and (F) PAr. BMI, body mass index, ALP, alkaline phosphatase, ALT, alanine aminotransferase; CRP, C-reactive protein; PLP, pyridoxal 5′-phosphate; PL, pyridoxal; PA, 4-pyridoxic acid.
Six-panel grouped forest plot depicting standardized beta coefficients and confidence intervals for various health parameters across males and females. Panels A to F represent PLP, PL, PA, PLP/PL, PLP/PA, and PAr, with parameters including age, BMI, ALP, ALT, eGFR, CRP, calcium, phosphorus, and albumin. Blue dots and bars show male data, orange indicates female data, illustrating gender differences for each variable per panel.Discussion
In this community-based sample of healthy Chinese adults, we established age- and sex- specific RIs for plasma vitamin B6 metabolites (PLP, PL, PA) and their ratios (PLP/PL, PLP/PA, PAr) using guideline-recommended robust methods, characterized age trends with sex-stratified percentile curves, and examined independent correlates in sex-stratified multivariable models. The percentile curves demonstrated clear age-associated distributional changes, supporting the use of sex- and age-specific RIs (<50 vs. ≥ 50 years) for clinical interpretation.
In this study, we found that vitamin B6 metabolism differed by age and sex, and the age-related decline in PLP was limited to males. This finding is consistent with the NHANES study on PLP levels in American adults (10). However, compared with American adults, the plasma PLP levels in our cohort was lower in males and higher in females. Additional analysis from NHANES also clarified the existence of race-related differences in PLP levels (10). These results suggest that race is an important factor affecting vitamin B6 homeostasis, and the RIs derived from Western populations cannot be directly applied to Chinese adults. Therefore, it is necessary to establish Chinese-specific RIs to ensure accurate assessment and clinical interpretation of vitamin B6 status. In our cohort, the median PLP concentration of all subgroups was above 30 nmol/L, which is the conventional adequacy threshold used to define the status of vitamin B6 sufficiency (1), indicating that our population is unlikely to exhibit significant PLP deficiency.
Our multivariate linear regression analyses found a strong correlation between ALP, eGFR, albumin, and phosphorus and vitamin B6 metabolites in both males and females. Specifically, serum ALP levels were strongly negatively correlated with plasma PLP levels and PLP based ratios, and positively correlated with PAr, which is consistent with the role of ALP in dephosphorylation from PLP to PL (2). Individuals with HPP are characterized by significantly elevated circulating PLP levels (15–17). In contrast, children diagnosed with familial hypophosphatemic rickets exhibit elevated levels of ALP and significantly reduced plasma PLP (21). Albumin was positively associated with PLP/PL and PLP/PA and inversely with PAr, supporting its function as a major PLP-binding protein and suggesting that reduced albumin may promote a more catabolic vitamin B6 profile (3). In previous studies, higher creatinine or lower eGFR were associated with increased PA and PAr, as well as decreased PLP (9, 22), which is consistent with the renal clearance of PA and our findings that renal function indicators shape PLP-PA balance.
It is worth noting that our study found a novel and independent association between serum level of phosphorus and vitamin B6 metabolism. The serum level of phosphorus was positively correlated with PLP, PLP/PL and PLP/PA, and negatively correlated with PAr. So far, the clinical connection between these two parameters is still unclear. We believe that this phenomenon can be explained by the regulatory mechanism of ALP activity. Inorganic phosphate is a recognized competitive inhibitor that affects ALP activity (23, 24). Therefore, higher physiological levels of serum phosphorus may lead to downregulation of ALP activity, thereby inhibiting ALP mediated degradation of PLP, and hindering cellular uptake of PLP, resulting in the accumulation of PLP in the plasma. Further mechanistic and longitudinal studies are needed to confirm whether the observed association represents a genuine physiological interaction between phosphorus homeostasis and vitamin B6 metabolism.
Based on these determinants, our sex-stratified age analyses revealed distinct patterns of vitamin B6 metabolism. In males, age-percentile curves and group comparisons (<50 vs. ≥ 50 years) showed lower PLP and PLP-based ratios and higher PAr in older compared with younger individuals, indicating a higher vitamin B6 turnover rate (6, 7). Older males also exhibited lower albumin, eGFR, and phosphorus (Supplementary Table 3), aligning with our regression results: reduced protein binding, diminished renal clearance capacity, and lower serum phosphorus together favor a more catabolic PLP–PA balance. In females, by contrast, PLP and related ratios remained relatively stable across all age groups, suggesting that sex-specific differences in hormonal or metabolic factors may attenuate age-related shifts observed in males. Collectively, these findings provide a mechanistic rationale for age- and sex-specific RIs and remind people not to generalize cutoff values that may misclassify elderly men or younger women.
This study has several limitations. Firstly, although strict exclusion criteria ensured internal validity, the overall and subgroup sample sizes were modest. Therefore, we applied Horn’s robust method, which is recommended by CLSI for small to medium samples and minimizes the influence of outliers. Nevertheless, moderate sizes can lead to wider confidence intervals for the estimated reference limits, particularly for upper limits, introducing statistical uncertainty. Larger scale and multicenter studies are warranted to validate and refine these RIs across diverse Chinese populations in the future. Secondly, we did not evaluate dietary vitamin B6 intake, the status of vitamin D, parathyroid hormone, or bone turnover markers, which may affect both ALP activity and vitamin B6 biomarkers (25, 26). Thirdly, the participants in this study were from Shanghai. Regional differences in dietary patterns, lifestyles, and socioeconomic status across China may affect the status and metabolism of vitamin B6. Therefore, external validation is still needed in multicenter cohorts from different regions. Lastly, previous prospective studies have linked high-turnover B6 profiles to adverse outcomes; the elderly males in our cohort exhibited such a pattern, suggesting a potentially less favorable phenotype. However, given the cross-sectional design and sex–age differences in eGFR, albumin, and mineral indices, this observation needs to be prospectively validated in the Chinese population.
Conclusion
In summary, we have established age- and sex-specific RIs for plasma PLP, PL, PA, and related ratios (PLP/PL, PLP/PA, and PAr) in healthy Chinese adults through rigorous screening, which can provide a reference baseline for clinical and laboratory evaluation of vitamin B6 metabolism. Meanwhile, a higher turnover rate of vitamin B6 was observed in elderly males. Serum ALP, albumin, renal function, and serum phosphorus are the four major factors significantly correlated with vitamin B6 status. Given the cross-sectional design of our study, the clinical prognostic significance of the high turnover vitamin B6 phenotype requires further validation in prospective cohorts of the Chinese population.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.
Ethics statement
The studies involving humans were approved by The Ethics Committee of Shanghai Sixth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
We thank all individuals for their participation in this study.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The handling editor YM declared a shared parent affiliation with the authors at the time of review.
Generative AI statement
The author(s) declared that Generative AI was used in the creation of this manuscript. Generative AI was used to assist with drafting and debugging analysis code (R scripts) for data processing, statistical modeling, and figure generation. All analyses were executed and verified by the authors, and the authors take full responsibility for the accuracy and integrity of the results.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2026.1782217/full#supplementary-material
ReferencesBjørke-MonsenA-LUelandPM. Vitamin B6: a scoping review for Nordic nutrition recommendations 2023. Food Nutr Res. (2023) 67:10259. doi: 10.29219/fnr.v67.10259UelandPMUlvikARios-AvilaLMidttunØGregoryJF. Direct and functional biomarkers of vitamin B6 status. Annu Rev Nutr. (2015) 35:33–70. doi: 10.1146/annurev-nutr-07AlbersenMBosmaMLuykxJJJansJJMBakkerSCStrengmanE. Vitamin B-6 vitamers in human plasma and cerebrospinal fluid. Am J Clin Nutr. (2014) 100:587–92. doi: 10.3945/ajcn.113.082008, 24808484AkiyamaTKubotaTMurayamaKFujiwaraMOhataYOzonoK. Vitamin B6 status in hypophosphatasia: association with clinical severity, diagnostic utility, and effects on vitamin B6 metabolism by supplementation and enzyme replacement therapy. J Inherit Metab Dis. (2025) 48:e70036. doi: 10.1002/jimd.70036, 40387451WhyteMPMcAlisterWHMackKEMummSMadsonKL. Pediatric hypophosphatasia: avoid diagnosis missteps!J Bone Miner Res. (2024) 39, 655–660. doi: 10.1093/jbmr/zjae098, 38905292SchorggPKaravasiloglouNBeyerACantwellMDanquahIGojdaJ. Increased vitamin B6 turnover is associated with greater mortality risk in the general US population: a prospective biomarker study. Clin Nutr. (2022) 41:1343–56. doi: 10.1016/j.clnu.2022.04.023, 35588551CuiQZhuXGuanGHuiRZhuLWangJ. Associations of vitamin B6 turnover rate with the risk of cardiovascular and all-cause mortality in hypertensive adults. Nutr Metab Cardiovasc Dis. (2023) 33:1225–34. doi: 10.1016/j.numecd.2023.03.017, 37085414ZhangDLiYLangXZhangY. Associations of serum vitamin B6 status and catabolism with all-cause mortality in patients with T2DM. J Clin Endocrinol Metab. (2022) 107:2822–32. doi: 10.1210/clinem/dgac429, 35907182HuangJYButlerLMMidttunØKohWPUelandPMWangR. Serum B(6) vitamers (pyridoxal 5′-phosphate, pyridoxal, and 4-pyridoxic acid) and pancreatic cancer risk: two nested case-control studies in Asian populations. Cancer Causes Control. (2016) 27:1447–56. doi: 10.1007/s10552-016-0822-6, 27830400SchiniMNicklinPEastellR. Establishing race-, gender- and age-specific reference intervals for pyridoxal 5′-phosphate in the NHANES population to better identify adult hypophosphatasia. Bone. (2020) 141:115577. doi: 10.1016/j.bone.2020.115577, 32791332AlbersenMBosmaMJansJJMHofstedeFCvan HasseltPMDe Sain-van Der VeldenMG. Vitamin B6 in plasma and cerebrospinal fluid of children. PLoS One. (2015) 10:e0120972. doi: 10.1371/journal.pone.0FootittEJClaytonPTMillsKHealesSJNeergheenVOppenheimM. Measurement of plasma B6 vitamer profiles in children with inborn errors of vitamin B6 metabolism using an LC-MS/MS method. J Inherit Metab Dis. (2013) 36:139–45. doi: 10.1007/s10545-012-9493-y, 22576361WhyteMPZhangFMackKEWenkertDGottesmanGSEricsonKL. Pyridoxine challenge reflects pediatric hypophosphatasia severity and thereby examines tissue-nonspecific alkaline phosphatase's role in vitamin B6 metabolism. Bone. (2024) 181:117033. doi: 10.1016/j.bone.2024.117033, 38307176DuddeFFildebrandtDSmeetsRGosauMAmlingMBeiklerT. Role of PLP-level as a predictive marker for oral health status in adult hypophosphatasia. Clin Oral Investig. (2024) 28:419. doi: 10.1007/s00784-024-05809-w, 38976034WhyteMP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. (2016) 12:233–46. doi: 10.1038/nrendo.2016.14, 26893260WhyteMPCoburnSPRyanLMEricsonKLZhangF. Hypophosphatasia: biochemical hallmarks validate the expanded pediatric clinical nosology. Bone. (2018) 110, 96–106. doi: 10.1016/j.bone.2018.01.022, 29360619WhyteMPMahurenJDVrabelLACoburnSP. Markedly increased circulating pyridoxal-5′-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism. J Clin Invest. (1985) 76:752–6. doi: 10.1172/JCI112031, 4031070InkerLASchmidCHTighiouartHEckfeldtJHFeldmanHIGreeneT. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. (2012) 367:20–9. doi: 10.1056/NEJMoa1114248, 22762315DavisSRLambrinoudakiILumsdenMMishraGDPalLReesM. Menopause. Nat Rev Dis Primers. (2015) 1:15004. doi: 10.1038/nrdp.2015.4, 27188659HornPSPesceAJCopelandBE. A robust approach to reference interval estimation and evaluation. Clin Chem. (1998) 44:622–31. doi: 10.1093/clinchem/44.3.622ReynoldsRDLorencRSWieczorekEPronickaE. Extremely low serum pyridoxal 5′-phosphate in children with familial hypophosphatemic rickets. Am J Clin Nutr. (1991) 53:698–701. doi: 10.1093/ajcn/53.3.698, 2000825VasilakiATMcMillanDCKinsellaJDuncanAO'ReillyDSJTalwarD. Relation between pyridoxal and pyridoxal phosphate concentrations in plasma, red cells, and white cells in patients with critical illness. Am J Clin Nutr. (2008) 88:140–6. doi: 10.1093/ajcn/88.1.140, 18614734CoburnSPMahurenJDJainMZubovicYWortsmanJ. Alkaline phosphatase (EC 3.1.3.1) in serum is inhibited by physiological concentrations of inorganic phosphate. J Clin Endocrinol Metab. (1998) 83:3951–7. doi: 10.1210/jcem.83.11.5288, 9814474MillánJL. The role of phosphatases in the initiation of skeletal mineralization. Calcif Tissue Int. (2012) 93:299–306. doi: 10.1007/s00223-012-9672-8, 23183786MorrisMSPiccianoMFJacquesPFSelhubJ. Plasma pyridoxal 5′-phosphate in the US population: the National Health and nutrition examination survey, 2003-2004. Am J Clin Nutr. (2008) 87:1446–54. doi: 10.1093/ajcn/87.5.1446, 18469270SchiniMVilacaTGossielFSalamSEastellR. Bone turnover markers: basic biology to clinical applications. Endocr Rev. (2023) 44:417–73. doi: 10.1210/endrev/bnac031
Edited by: Yanhui Ma, Shanghai Jiao Tong University, China
Reviewed by: Jingjing Wei, Shanxi Medical University, China